Article Category: Original article
Published Online: Feb 04, 2017
Page range: 683 - 692
DOI: https://doi.org/10.5372/1905-7415.0605.108
Keywords
© 2017
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Background: Study of antiangiogenic drugs is one of the cutting-edge fields in new antitumor drug development. However, system studies on Vaccaria segetalis extract as an inhibitor of tumor-induced neovascularization have not been published yet. In the current study, we performed a preliminary investigation of the antiangiogenic effect of Vaccaria segetalis extract on angiogenesis.
Objective: We studied the inhibitory effect of Vaccaria segetalis extract on neovascularization.
Methods: The effects of Vaccaria segetalis extract on in vitro proliferation, migration, and tube formation of human mammary endothelial cells (HMECs) were determined by 3 - (4,5) - dimethylthiahiazo (-z-y1) - 3, 5 -diphenytetrazoliumromide (MTT) assay and Matrigel plug assay. The antiangiogenic effect of Vaccaria segetalis extract was observed on the chick chorioallantoic-membrane (CAM) angiogenesis model. The CD31 expression on HMECs was detected by immunohistochemical staining. The therapeutic effect of Vaccaria segetalis extract on the metastasis of Lewis lung cancer was also observed in the mouse model.
Results: The proliferation and migration of human mammary epithelial cells (HMECs) were inhibited significantly by Vaccaria segetalis extract in a dose-dependent manner (IC50 = 50 μg/mL). Angiogenesis was also inhibited in the Matrigel-plug mouse model and the chick chorioallantoic-membrane model. The Vaccaria segetalis extract treatment reduced the expression of CD31 in HMECs and inhibited the growth and metastasis of Lewis lung carcinoma cells in the mouse model.
Conclusion: The Vaccaria segetalis extract, which can obviously inhibit angiogenesis, could be developed as a promising new antiangiogenic drug.